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The extracellular matrixmolecule tenascin-C (TNC) is
a major component of the cancer-specific matrix,
and high TNC expression is linked to poor prognosis
in several cancers. To provide a comprehensive un-
derstanding of TNC’s functions in cancer, we estab-
lished an immune-competent transgenic mouse
model of pancreatic b-cell carcinogenesis with
varying levels of TNC expression and compared
stochastic neuroendocrine tumor formation in abun-
dance or absence of TNC. We show that TNC
promotes tumor cell survival, the angiogenic switch,
more and leaky vessels, carcinoma progression, and
lung micrometastasis. TNC downregulates Dick-
kopf-1 (DKK1) promoter activity through the blocking
of actin stress fiber formation, activates Wnt
signaling, and induces Wnt target genes in tumor
and endothelial cells. Our results implicate DKK1
downregulation as an important mechanism underly-
ing TNC-enhanced tumor progression through the
provision of a proangiogenic tumor microenvi-
ronment.482 Cell Reports 5, 482–492, October 31, 2013 ª2013 The AuthorsINTRODUCTION
Manifestation of cancer requires many steps in which the micro-
environment plays an essential role (Bissell and Labarge, 2005).
A group of tumor cells with oncogenic mutations does not readily
cause cancer, a phenomenon known as tumor dormancy
(Aguirre-Ghiso, 2007). Angiogenesis presents an important
step in awakening quiescent tumors and in driving their develop-
ment into metastatic cancer (Almog, 2010). Tumor cells secrete
soluble factors that attract endothelial cells (Kerbel, 2008). In
addition, the extracellular matrix (ECM) constitutes a major frac-
tion of cancer tissue and contributes to tumor angiogenesis and
metastasis (Lu et al., 2012). An important component of the
tumor-specific ECM is tenascin-C (TNC). TNC is known to pro-
mote malignant tumor progression and lung metastasis; yet,
the underlying mechanisms are poorly understood (Midwood
et al., 2011).
Because no stochastic and immune-competent in vivo model
existed that would recapitulate the roles of TNC in tumor pro-
gression, we generated mouse lines with different expression
levels of TNC (overexpression, wild-type, knockout) in the Rip1-
Tag2 (RT2) model of pancreatic b-cell carcinogenesis (Hanahan,
1985). This model recapitulates multistage tumorigenesis as
observed in most human cancers (Nevins, 2001; Pipas and Lev-
ine, 2001).
Here, we demonstrate that TNCpromotes several steps in RT2
tumorigenesis including the angiogenic switch and lung micro-
metastasis. We provide a mechanistic basis showing that TNC
downregulates expression of the soluble Wnt inhibitor Dick-
kopf-1 (DKK1) (Glinka et al., 1998) by blocking actin stress fiber
formation and induces canonical Wnt signaling in tumor and
endothelial cells. Our data suggest that DKK1 downregulation
by TNC in tumor and stromal cells may provide a tumorigenesis
signaling promoting microenvironment. Given that Wnt signaling
is a crucial pathway driving angiogenesis and is activated by
TNC, this pathway may play an important role in promoting
tumor angiogenesis and metastasis by TNC. Thus, targeting
TNC or its associated signaling pathways may represent a strat-
egy to counteract tumor progression.
RESULTS
Tenascin-CPromotes TumorCell Survival, Proliferation,
and Invasiveness
To address whether TNC potentially plays a role in the RT2
model (Hanahan, 1985), we determined TNC expression during
RT2 tumorigenesis by immunofluorescencemicroscopy analysis
(immunofluorescence [IF]). In normal pancreatic islets, TNC
expression was undetectable, whereas a large fraction of hyper-
plastic and almost all angiogenic and tumorigenic islets ex-
pressed TNC (Figure S1A), suggesting a potential role of TNC
during RT2 tumor progression. Therefore, we generated RT2
mice with overexpression of TNC (RT2/TNC) and a lack of TNC
(RT2/TNCKO) (Figures S1B–S1G).
We performed tissue analysis to address whether ectopically
expressed TNC had an effect on cell proliferation. We quantified
the proportion of cells positive for phosphohistone-H3 by IF
(Figure S2A) and observed that tumors of RT2/TNC mice ex-
hibited 1.4-fold more proliferating cells than those from RT2
mice (Figure 1A) with a significant difference in hyperplastic is-
lets (Figure S2C). Surprisingly, a similar difference was also
seen in RT2/TNCKO tumors (Figures 1B and S2D). We also
investigated a potential impact of ectopically expressed TNC
on apoptosis by staining for cleaved caspase-3 (Figure S2B).
RT2/TNC tumors exhibited 2.8-fold less apoptotic cells than
RT2 wild-type tumors (Figures 1C and S2E). In contrast,
apoptosis was unchanged in RT2/TNCKO tumors in comparison
to RT2 controls (Figures 1D and S2F). However, no difference
was seen in tumor multiplicity or tumor volume between geno-
types (Figures S2G and S2H). Interestingly, upon tumor grading
we observed that the frequency of carcinomas and the ratio of
carcinomas over adenomas were higher in RT2/TNC mice
(1.8) than in RT2 controls (0.8) (Figure 1E; Table S1). We
conclude that transgenic TNC increases proliferation and sur-
vival in RT2/TNC mice and more importantly promotes tumor
progression.
Tenascin-C Promotes the Angiogenic Switch and the
Formation of Leaky and Abnormal Tumor Vessels
To address whether TNC has an effect on RT2 tumor angiogen-
esis, we isolated islets at the age of 8weekswhen the angiogenic
switch takes place in a subset of neoplastic islets (Hanahan et al.,
1996; Parangi et al., 1996) (Figure S2I). We noticed that the num-Cber of angiogenic islets was 2.4-fold higher in RT2/TNC and 2.9-
fold lower in RT2/TNCKO mice in comparison to RT2 littermates
(Figures 1F and 1G; Table S2). By quantification of CD31-posi-
tive endothelial cells (Figure S2J) in tumor sections of 12-
week-old RT2 mice, we observed that the abundance of blood
vessels was 2.6-fold higher and 1.6-fold lower in tumors of
RT2/TNC and RT2/TNCKO mice, respectively, than in RT2 con-
trols (Figures 1H and 1I).
We next addressed the question of a potential impact of TNC
on vessel anatomy by scanning electron microscopy in Mercox
corrosion casts of the tumor vasculature of multiple tumors of
RT2 and RT2/TNC mice. Using this descriptive approach, we
observed a highly aberrant vessel phenotype in some RT2/
TNC tumors that has not been seen in RT2 tumors. These ves-
sels were irregularly shaped, wider, discontinued, and bifurcated
(see arrows), reminiscent of high vessel branching and/or
leakage (Figures 1J and S2K). Because this approach is not suit-
able for quantitative determinations, we then studied vessel
lining by pericytes using NG2 staining as readout for vessel
functionality and maturation (Figure S2L). Despite more abun-
dant pericytes in RT2/TNC tumors (Figure S2M), quantification
of combined NG2 and CD31 staining signals revealed a 23.7%
reduced ratio of NG2 over CD31 in RT2/TNC tumors (Figure 1K),
which is indicative of a reduced pericyte coverage of vessels
(Song et al., 2005). Finally, we assessed vessel functionality by
analyzing fibrinogen (FBG) leakage in tumors upon PBS perfu-
sion of tumor vessels followed by FBG staining (Huijbers et al.,
2010) (Figure S2N). Whereas FBG leakage was slightly increased
(close to significance, p = 0.064) in RT2/TNC over control tumors
(Figures 1L and S2O), this analysis revealed a 1.7-fold signifi-
cantly reduced FBG staining in RT2/TNCKO tumors over RT2
wild-type tumors (Figures 1M and S2P).
Altogether, our results suggest that, whereas TNC promotes
the angiogenic switch and increases tumor blood vessel density,
it decreases vessel coverage by pericytes and increases
leakage, thus perturbing tumor vessel functionality.
Tenascin-C Increases Lung Micrometastasis
In a C57Bl/6 background, RT2 mice do not exhibit macroscopi-
cally visible metastasis. To address whether TNC had an effect
on micrometastasis formation, we determined expression of
insulin (as tumor cell-specific marker) in liver and lung tissue of
tumor-bearing mice. Upon tissue staining, we detected cohorts
of insulinoma cells within liver and lung tissue confirming their
metastatic nature (Figures 2A and S3A). Hematoxylin and eosin
(H&E) staining revealed their parenchymal localization. In a
subset of mice, we compared quantification of insulin by im-
munostaining and quantitative RT-PCR (qRT-PCR). This showed
a good correlation between both methods and indicates that
quantification by qRT-PCR reflects parenchymal localization of
micrometastasis rather than circulating tumor cells. We then
analyzed a larger sample size of liver and lung tissue by qRT-
PCR. Although we did not observe differences in liver tissue
between genotypes (Figures S3B and S3C), insulinmRNA levels
in lungs of RT2/TNC mice were 5.4-fold higher in comparison
to lungs of RT2 controls (Figure 2B). Moreover, we observed
28.3-fold lower insulin mRNA levels in lungs of mice lacking
TNC in comparison to control littermates carrying one TNC alleleell Reports 5, 482–492, October 31, 2013 ª2013 The Authors 483
Figure 1. TNC Enhances Proliferation, Survival, and Tumor Progression in RT2 Tumors
(A and B) Quantification of proliferating cells in tumor sections as PH3-positive nuclei in 12-week-old mice. (A) RT2 (n = 9 mice, n = 150 islets), RT2/TNC (n = 8,
n = 140). (B) RT2 (n = 6, n = 131) and RT2/TNCKO (n = 6, n = 137).
(C and D) Quantification of apoptotic cells as cleaved caspase-3-positive cells in tumor sections of 12-week-oldmice. (C) RT2 (n = 6mice, n = 84 islets), RT2/TNC
(n = 8, n = 123). (D) RT2 (n = 4, n = 95) and RT2/TNCKO (n = 4, n = 83).
(E) Tumor grading into adenoma or invasive carcinoma (H&E-stained tumor sections) of RT2 tumors (n = 26 mice, 78 adenomas, 79 carcinomas) and RT2/TNC
(n = 22, 44 adenomas, 76 carcinomas). See Table S1.
(F and G) Number of angiogenic islets per mouse normalized to RT2 controls. See Table S2.
(H and I) Tumor blood vessel quantification upon CD31 staining of tumor sections from 12-week-old mice as CD31-positive area fraction per tumor normalized to
RT2 controls. (H) RT2 (n = 6 mice, n = 34 tumors, 203 images) and RT2/TNC (n = 4, n = 17, 106 images). (I) RT2 (n = 3, n = 71) and RT2/TNCKO (n = 3, n = 111).
(J) Morphology of the tumor vasculature in Mercox perfusion casts from 12-week-old RT2 and RT2/TNC mice. Arrows point at break point, branching, and
constriction. Scale bars, 50 mm.
(K) Pericyte coverage of tumor blood vessels upon quantification of the ratio of NG2 over CD31 staining signals. RT2 (n = 6 mice, n = 155 tumors) and RT2/TNC
(n = 8, n = 204).
(L and M) Quantification of tumor blood vessel leakage upon fibrinogen staining of tumor sections from 12-week-old mice as fibrinogen-positive area fraction per
tumor. (L) RT2 (n = 5mice, n = 62 tumors) and RT2/TNC (n = 3, n = 50). (M) RT2 (n = 4, n = 60) and RT2/TNCKO (n = 5, n = 125). Error bars represent SEM. *p < 0.05.
See also Figures S1 and S2 and Tables S1 and S2.(Figure 2C). Our results suggest that in the RT2 model TNC does
not affect liver metastasis but increases lung micrometastasis
formation.
TNC Expression Correlates with Low Dkk1 Levels and
Increases Wnt Target Gene Expression
Because we had noticed downregulation of the Wnt pathway
inhibitor DKK1 in T98G glioblastoma cells cultivated on a TNC-
containing substratum (Ruiz et al., 2004), we assessed a poten-484 Cell Reports 5, 482–492, October 31, 2013 ª2013 The Authorstial impact of TNC on Dkk1 expression in tumors of the different
RT2 genotypes. By qRT-PCR, we noticed that 12 times more
RT2/TNC tumors (46.1%) lacked Dkk1 expression as compared
to RT2 controls (3.7%) (Figure 3A). In RT2/TNC tumors with
detectable Dkk1 expression, the levels were 16.1-fold reduced
in comparison to RT2 controls (Figure 3B). In contrast, Dkk1
levels were 2.6-fold higher in tumors lacking TNC as compared
to control tumors with one TNC allele (Figure 3C). These obser-
vations demonstrate an inverse correlation between TNC and
Figure 2. Lung Micrometastasis in RT2 Mice
Insulin expression in a lung RT2 micrometastasis (A) and quantification by
qRT-PCR (B and C). (A) Detection of metastasized insulin-positive tumor cells
in lung parenchyma (RT2 mouse) by immunostaining (upper panel) and H&E
staining (adjacent section, lower panel). Scale bar 50 mm. Detection of insulin
expression in RT2 (9/24) and RT2/TNC mice (11/24) (B) and in RT2/TNC+/
(8/13) and RT2/TNCKO littermates (4/13) (C). Error bars represent SEM. *p <
0.05. See also Figure S3.
Figure 3. Dkk1 Expression in RT2 Tumors
(A) Tumors were stratified according to Dkk1 levels, as Dkk1 expressing
(Dkk1+) or not expressing (Dkk1). Dkk1was found to be expressed in 26 of 27
RT2 tumors and in 7 of 13 RT2/TNC tumors. Difference between genotypes,
p < 0.05.
(B) Dkk1 expression was largely reduced in those RT2/TNC tumors with
detectable Dkk1 expression. Axin2 expression was enhanced in RT2/TNC
tumors.
(C) In RT2/TNCKO tumors (15 of 24 tumors were Dkk1 positive) Dkk1
expression was higher compared to RT2/TNC+/ tumors (16 of 23 tumors were
Dkk1 positive). Axin2 expression was not changed.
(A–C) Dkk1 and Axin2 expression was analyzed by qRT-PCR.
(A–D) Wnt target gene expression in all RT2/TNC and RT2/TNCKO tumors
(A–C) or in small differentiated tumors (D), see Table S3. Error bars represent
SEM. *p < 0.05.Dkk1 expression and suggest that TNC may activate Wnt
signaling through Dkk1 repression. To address this possibility,
we determined the expression of Wnt target genes by qRT-
PCR. We observed an increased expression of the bona fide
Wnt signaling target Axin2 (1.4-fold) in RT2/TNC tumors (Fig-
ure 3B), whereas its expression was unchanged in RT2/TNCKO
tumors (Figure 3C). This result suggested that ectopic TNC
expression induced Wnt signaling, prompting us to analyze
expression of other Wnt target genes. Indeed, other Wnt targets
such as Cyclin D1 (2.0-fold), CD44 (2.0-fold), and Slug (1.8-fold)
were upregulated in small differentiated tumors of RT2/TNC
mice (Figure 3D; Table S3). These results suggest that TNC
may contribute to Wnt signaling activation in RT2/TNC tumors
through downregulation of the inhibitor Dkk1.
Wnt Activation and DKK1 Inhibition by TNC in Cultured
Tumor and Stromal Cells
We then designed in vitro experiments to evaluate a potential
Wnt activation by TNC involving DKK1. We used a Wnt reporter
(TOPFlash) assay where the expression of the luciferase gene is
driven by a promoter containing TCF/LEF binding sites. Upon
growth of Wnt-3A-stimulated osteosarcoma KRIB cells on a
TNC-containing substratum, we observed a 3.5-fold increasedCWnt reporter activity (Figure 4A) and a 2.0-fold increased expres-
sion of AXIN2 (Figure 4B), demonstrating that TNC activates the
Wnt pathway.
Next, we determined whether TNC affects secretion of soluble
factors regulating Wnt signaling in KRIB cells. Therefore, we
measured Wnt reporter activity of Wnt-3A-stimulated KRIB cells
upon incubation with conditioned medium (CM) from the same
cells previously grown on fibronectin (FN) or FN/TNC and
observed that, indeed, Wnt activity was higher with CM from
cells cultured in the presence of TNC (Figure 4C). These results
suggest that TNC activates Wnt signaling through modulating
the secretion of activators or inhibitors of the Wnt pathway.
To address whether Wnt inhibitors are regulated by TNC, we
investigated their expression by qRT-PCR in cells grown on
FN/TNC and FN. Although some inhibitors (DKK4 and SFRP2)ell Reports 5, 482–492, October 31, 2013 ª2013 The Authors 485
Figure 4. TNC Leads to DKK1 Downregulation and Wnt Signaling Activation in Tumor Cells and Endothelial Cells
(A–C) EnhancedWnt signaling in Wnt-3A-treated KRIB cells by TNC. TOPFlash activity of cells grown on FN or FN/TNC for 48 hr (A) or treated for 48 hr with Wnt-
3A CM and CM of cells grown on FN or FN/TNC (C). (B) AXIN2 mRNA levels (qRT-PCR, 5 hr).
(D)DKK1 expression (qRT-PCR, 24 hr) in the indicated tumor cell lines (KRIB, T98G, MDA-MB-435 [MDA], MCF-7, and Caco2) on FN/TNC is represented relative
to its expression on FN.
(E) Cell autonomous impact of low (knockdown) and high (overexpression) DKK1 on Wnt signaling as analyzed by TOPFlash activity after 48 hr.
(F) Repression of TNC-mediated Wnt signaling activation by Dkk1. TOPFlash luciferase activity was performed as in (A) except the addition of CM from KRIB
control or Dkk1-overexpressing cells after 5 hr of cell seeding on the indicated substrata. Note that the TNC-containing substratum still induced Wnt signaling
activity in presence of Dkk1-containing CM, but to a lesser extent (1.8-fold) than in the control conditions (3.1-fold).
(G–I) DKK1 and Axin2 mRNA levels in pericytes (G and H) and two human colorectal-cancer-derived CAF primary lines (I) seeded on FN or FN/TNC (5 hr). TNC
leads to downregulation of DKK1 in pericytes and CAFs (G and I), but AXIN2 expression remains unchanged in pericytes (H).
(J–L) EnhancedWnt signaling by TNC inHUVECs. qRT-PCR for DKK1 and AXIN2 (5 hr) (J and L) andDKK1 immunoblotting (24 hr) (K). Data from three independent
experiments (except D: MCF-7 and Caco2 cell lines, one and two experiments, respectively; and I: two experiments) are shown as mean ± SEM. *p < 0.05.
See also Figure S4.were not expressed, no consistent effect of TNC was observed
on the expression of other analyzed Wnt inhibitors (DKK2,
DKK3, SFRP1, SFRP3, SFRP4) in KRIB, T98G, andMDA-MB435
cells (Figure S4A). In contrast, we observed a robust downregu-
lation of DKK1 in all five analyzed tumor cell lines of different
origin after 24 hr on the TNC-containing substratum (Figures
4D and S4A). DKK1 downregulation was observed at both
RNA and protein levels, with a fast (5 hr) and long-lasting (up to
12 days) effect in T98G cells (Figures S4B and S4C).486 Cell Reports 5, 482–492, October 31, 2013 ª2013 The AuthorsTo determine whether modulation of DKK1 expression
contributes to TNC-dependent Wnt signaling in KRIB cells,
TOPFlash activity was measured upon overexpression and
knockdown of DKK1, respectively (Figures S4D–S4G). Indeed,
activity of the Wnt signaling reporter was DKK1 dependent
because it was increased upon DKK1 knockdown and
decreased upon Dkk1 overexpression (Figure 4E) and was
repressed by Dkk1-containing CM in a dose-dependent manner
(Figure S4H). When KRIB cells were incubated with Dkk1 CM on
Figure 5. Mechanism of DKK1 Downregulation
(A) Reduced DKK1 promoter activity by TNC. DKK1 promoter driven luciferase activity in T98G cells is shown upon growth for 48 hr on the indicated substrata.
(B and E) Phalloidin (red) and vinculin (green) stainings of serum-starved T98G cells upon CTR, CD (2 mM), or LB (5 mM) treatment for 3 hr (B). Nuclei are stained in
blue (DAPI). Scale bar 20 mm.
(C and D) DKK1 mRNA levels in serum-starved T98G upon LB (5 mM, 3 hr) (C) or CD (2 mM, 3 hr) (D) treatment.
(E) IF staining of T98G cells upon control or LPA (30 mM) treatment. Serum-starved T98G were plated on fibronectin (FN) or fibronectin/tenascin-C (FN/TNC), and
after 1 hr LPAwas added for 4 hr. Although cells are poorly spread under control conditions on FN/TNC (no actin stress fibers, few focal adhesions), LPA treatment
restored cell spreading associated with the formation of focal adhesions and actin stress fibers. Scale bar, 20 mm.
(F) DKK1 mRNA expression determined by qRT-PCR upon treatment with 30 mM LPA. LPA restores DKK1 expression on FN/TNC.
(G–I)DKK1mRNA expression determined by qRT-PCR upon ectopic expression of chicken syndesmos (G) andmouse TPM1 (H) or upon knockdown of TPM1 (I).
Syndesmos or TPM1 overexpression induces DKK1 mRNA expression, whereas TPM1 knockdown leads to DKK1 downregulation.
Data are shown as mean ± SEM. *p < 0.05. See also Figure S5.FN/TNC and FN, Wnt reporter activity was largely reduced
(Figure 4F), suggesting that TNC-induced repression of DKK1
facilitates Wnt pathway activation.
Next, we determined whether stromal cells also downregu-
lated DKK1 on a TNC substratum. Therefore, DKK1 expression
was determined in two monocytic/macrophage cell lines, pri-
mary human brain pericytes, two colorectal cancer derived
carcinoma associated fibroblasts (CT5.1, CT14), and human
umbilical vein endothelial cells (HUVECs) upon growth on FN/
TNC and FN. We noticed that in contrast to the two macrophage
lines that did not at all express DKK1, pericytes (5-fold), CAFs
(3.0- and 1.6-fold), and HUVECs (2.2-fold) significantly downre-
gulated DKK1 mRNA (Figures 4G, 4I, and 4J) and protein (Fig-
ure 4K) on a TNC substratum. Whereas Axin2 expression was
not affected in pericytes (Figure 4H), Axin2 mRNA was 2.3-fold
increased in HUVECs on FN/TNC in comparison to FN (Fig-
ure 4L). Altogether, our results show that TNC induces downre-
gulation of DKK1 in tumor and stromal cells and activates Wnt
signaling in tumor and endothelial cells.
Mechanism of DKK1 Downregulation by TNC
First, we determined whether DKK1 mRNA stability is substra-
tum dependent. Therefore, T98G cells were treated with theCRNA polymerase II inhibitor Actinomycin D, but DKK1 mRNA
levels were equally low in cells on FN and FN/TNC, suggesting
that DKK1 is not regulated by mRNA stabilization (Figure S5A).
Next, we addressed whether TNC downregulates DKK1 at tran-
scriptional level. Therefore, we performed reporter assays by
measuring luciferase activity under control of a 3.2 kbDKK1 pro-
moter sequence. Indeed, we observed a 2.5-fold reduced DKK1
promoter activity in cells grown for 48 hr on a TNC-containing
substratum (Figure 5A).
Because TNC blocks actin stress fiber formation (Huang et al.,
2001; Midwood et al., 2004; Murphy-Ullrich et al., 1991; Orend et
al., 2003), we investigated whether disruption of the actin cyto-
skeleton has an impact on DKK1 mRNA levels. Treatment with
Latrunculin B (LB) andCytochalasin D (CD) disrupted actin stress
fibers and focal adhesions and, importantly, reduced DKK1
expression (Figures 5B–5D). To address the converse whether
more actin stress fibers stimulate DKK1 expression, we treated
KRIB and T98G cells with lysophosphatidic acid (LPA) and
observed an increased and dose-dependent DKK1 mRNA
expression similar to serum response factor (SRF), a known actin
stress fiber-regulated gene (Gineitis and Treisman, 2001;
Spencer and Misra, 1999) (Figures S5B–S5F). Moreover, LPA
(30 mM) restored cell spreading, actin stress fibers, and focalell Reports 5, 482–492, October 31, 2013 ª2013 The Authors 487
Figure 6. Dkk1 Overexpression Inhibits
Osteosarcoma Growth and Angiogenesis
(A)Mean tumor volume of control (CTR, n = 10) and
Dkk1-overexpressing (n = 9) KRIB tumors upon
subcutaneous injection of the corresponding cells
into nude mice.
(B) Representative tumor images.
(C) Tumor microvessel density, as determined by
CD31 staining and quantification, was 2.2-fold
reduced in KRIB:Dkk1 tumors (n = 8) as compared
to control KRIB tumors (n = 10).
Error bars represent SEM. *p < 0.05. See also
Figure S6.adhesions in T98G cells on a FN/TNC substratum and most
importantly largely restored DKK1 levels on this substratum to
that on FN (Figures 5E and 5F). Because LPA can trigger RhoA
signaling (Mills and Moolenaar, 2003), and RhoA expression
(Lange et al., 2007) and function (Wenk et al., 2000) are impaired
by TNC, we determined whether overexpression of a constitu-
tively active (CA) RhoA molecule impacts on DKK1 expression.
Whereas, CA-RhoA increased SRF target gene expression (Fig-
ures S5G–S5J), it did not alter DKK1 expression (Figures S5K
and S5L), suggesting that LPA triggers DKK1 expression by a
RhoA-independent pathway.
Because tropomyosin-1 (TPM1) and syndesmos overexpres-
sion bypass the cell adhesion blocking and actin stress-fiber-
disrupting effect of TNC on a FN/TNC substratum (Lange et al.,
2008), we determinedwhether ectopic expression of syndesmos
and TPM1 have an impact on DKK1 expression. Whereas
shTPM1 blocked DKK1 expression, overexpression of syndes-
mos and TPM1 increased DKK1 mRNA levels to 4.7- and 3.6-
fold, respectively (Figures 5G–5I and S5M–S5P).
Altogether, these results demonstrated that DKK1 expression
is regulated at the promoter level and that actin stress fibers and
focal adhesion signaling drive DKK1 transcription independently
of RhoA. We conclude that TNC downregulates DKK1 transcrip-
tion by blocking focal adhesion and actin stress fiber formation.
Repression of Tumor Angiogenesis by DKK1
As we observed that TNC promotes tumor angiogenesis and
downregulates DKK1 expression, we addressed whether
DKK1 impacts on tumor angiogenesis in xenografted tumors of
KRIB cells with different DKK1 levels. We found that upon
Dkk1 overexpression (Figure S6A) tumors were significantly
smaller (Figure 6A) and pale (Figure 6B). Quantification of micro-
vessel density upon CD31 staining revealed that Dkk1-overex-
pressing tumors were less vascularized (Figure 6C), suggesting
that Dkk1 overexpression impaired tumor angiogenesis. In addi-
tion, conditioned medium from KRIB cells overexpressing Dkk1
inhibited HUVEC tubulogenesis on Matrigel in vitro (Figure S6D).
We addressed whether Dkk1 potentially had an impact on tumor
growth through inhibiting tumor cell proliferation and found no
statistically significant difference in proliferation in cultured cells
or in the tumorswith elevatedDkk1 levels (Figures S6B andS6C).488 Cell Reports 5, 482–492, October 31, 2013 ª2013 The AuthorsBecause Dkk1 influenced proliferation of
tumor cells neither in vitro nor in vivo,
our data suggest that Dkk1 overexpres-sion impairs angiogenesis and thereby inhibits KRIB tumor
growth. Because DKK1 blocks angiogenesis in a VEGFA context
(Min et al., 2011), we investigated whether full-length TNC binds
VEGFA. Indeed, by surface plasmon resonance we observed a
dose-dependent binding of VEGFA to TNC (Figure S7), extend-
ing data on binding of VEGFA to the fifth FNIII domain in TNC
(De Laporte et al., 2013) by providing a Kd of 2.73 10
7 M, which
is in the range of a VEGFA/glycosaminoglycan interaction (2.43
108 M) (Wu et al., 2009).
TNC Expression in Human Insulinomas
As we demonstrated a tumor-promoting effect of TNC in the
murine RT2 insulinoma model, we assessed a potential clinical
relevance by determining TNC expression in human insulinomas
using qRT-PCR and immunohistochemical staining of patient
tumor tissue. Of note, insulinomas are rare and most are benign,
yet a few (10%–15%)metastasize to lymph nodes and liver (Metz
and Jensen, 2008). At RNA level, we found that TNC expression
was detectable in all analyzed human insulinomas (Figure 7A).
Most importantly, we observed the highest TNC expression
levels (3/14) in tumors from patients with metastasis to liver or
lymph nodes (Figures 7A and 7B), suggesting that a high TNC
expression correlates with metastasis formation in human
insulinomas.
DISCUSSION
We have used the RT2 model of multistage pancreatic b-cell
tumorigenesis with abundant and no TNC expression to obtain
a better understanding of TNC contribution to tumor progression
and we have observed multiple effects. Enhanced TNC levels in
TNC transgenic RT2mice correlate with an increase in tumor cell
proliferation and survival, carcinoma formation, angiogenesis,
and lung micrometastasis. On the contrary, the absence of
TNC results in reduced angiogenesis and lung micrometastasis.
These results confirm a crucial role of TNC in tumor progression
as has been suspected in human cancer.
There is much evidence for an important role of TNC in pro-
moting tumor angiogenesis (Midwood et al., 2011). However,
despite the fact that TNC has been extensively investigated for
almost three decades (Chiquet-Ehrismann et al., 1986), it is not
Figure 7. TNC Expression Correlates with Metastasis Formation in
Human Insulinomas
(A) TNCmRNA expression was determined by qRT-PCR in two patient groups
(group 1, Munich cohort; group 2, Strasbourg cohort) and is displayed as
relative expression upon normalization toGAPDH. Upon combining data of the
two groups, TNC expression in patients with metastasis is increased over that
in patients without metastasis (p < 0.05).
(B) TNC expression was determined by IHC in all tumors of the two groups of
insulinomas. Representative pictures of the three metastatic and three non-
metastatic insulinomas are shown. Scale bar, 100 mm.resolved how TNC impacts tumor angiogenesis at the molecular
level. Whereas TNC can have stimulatory effects on endothelial
cell migration, conflicting reports exist concerning its impact
on tubulogenesis. A proangiogenic effect of TNC linked to
VEGFA expression was seen in humanmelanoma xenografts im-
planted into immune-compromised mice lacking TNC (Tanaka
et al., 2004). Of note, in the RT2/TNC tumors we did not observe
an increased VEGFA expression (M.K., F.S., G.O., unpublished
data). Our study addresses the role of TNC on tumor angiogen-Cesis systematically by using a stochastic genetic tumor model
with an intact immune system. Here, we investigated the angio-
genic switch, tumor blood vessels, and their functionality. Most
importantly, our study shows that TNC promotes the angiogenic
switch, a rate-limiting step along tumor progression (Hanahan
and Folkman, 1996), and the abundance of endothelial cells.
However, TNC seems to impair vessel functionality because tu-
mor vessels of RT2/TNC mice are morphologically aberrant and
less covered by pericytes. Moreover, vessels in RT2 tumors
lacking TNC are less leaky than those with TNC, suggesting a
role of TNC in the formation of more but less functional tumor
vessels.
We have identified DKK1 as an important TNC target in RT2
tumors. Our in vivo and in vitro results suggest that TNC pro-
motes tumor progression involving DKK1 downregulation and
activation of Wnt signaling. First, the TNC copy number inversely
correlates with DKK1 expression in RT2 tumors, and a TNC sub-
stratum downregulates DKK1 expression in tumor and several
stromal cell types (CAFs, pericytes, and endothelial cells). Sec-
ond, Wnt signaling is increased by TNC in the RT2 model and
in cultured endothelial and tumor cells. Third, TNC-induced
Wnt activation is reduced in tumor cells by DKK1. Finally, down-
regulation ofDKK1 by TNCmay be a key event because no other
major Wnt inhibitor is consistently regulated by a TNC-contain-
ing substratum (our data; Ruiz et al., 2004).
Several transcriptional regulators, epigenetic silencing, and
tissue tension were shown to regulate DKK1 expression (Agui-
lera et al., 2006; Barbolina et al., 2013; Liao et al., 2008; Menezes
et al., 2012; Penda´s-Franco et al., 2008; Zhou et al., 2012). Here,
we demonstrate that TNC downregulates DKK1 expression by
promoter inhibition. Because TNC blocks actin stress fiber for-
mation (Huang et al., 2001; Midwood et al., 2004; Murphy-Ullrich
et al., 1991; van Obberghen-Schilling et al., 2011), we investi-
gated whether DKK1 expression is regulated by the actin poly-
merization state and demonstrated that TPM1 antisense and
drug-induced disruption of the actin cytoskeleton reduced
DKK1mRNA levels. On the contrary, enforcing actin polymeriza-
tion and stress fiber formation by overexpression of syndesmos,
bridging integrin a5b1 and syndecan-4 in focal adhesions (Bass
and Humphries, 2002), largely increased DKK1 expression. We
further showed that LPA rescued focal adhesion and actin stress
fiber formation and cell spreading on FN/TNC,whichwe linked to
restored DKK1 expression in a RhoA-independent manner. How
TNC downregulates DKK1 expression at promoter level is
currently unknown and requires further investigation, but it
does not appear to be exclusively dependent on the SRF cotran-
scription factor MKL1 that is regulated by actin polymerization
(Miralles et al., 2003) (A.S. and G.O., unpublished data). Previ-
ously, it was shown that a stiffened collagen substratum, impli-
cating integrin adhesion signaling (Levental et al., 2009), induces
DKK1 downregulation in several cell types including endothelial
cells (Barbolina et al., 2013). Here, we report a mechanism
whereby TNC blocks DKK1 transcription through disruption of
actin stress fibers.
The role of DKK1 in developmental and tumor angiogenesis
appears to be context dependent, because DKK1 can pro-
duce pro- and antiangiogenic effects (Aicher et al., 2008; De
Langhe et al., 2005; Min et al., 2011; Oh et al., 2012; Reisell Reports 5, 482–492, October 31, 2013 ª2013 The Authors 489
et al., 2012; Smadja et al., 2010). Interestingly, the growth factor
context seems to be particularly critical for the outcome,
because, for example, DKK1 promotes basic fibroblast-
growth-factor-induced angiogenesis (Aicher et al., 2008; Reis
et al., 2012; Smadja et al., 2010) but blocks VEGFA-induced
(Min et al., 2011) angiogenesis in Matrigel plug assays in vivo.
We here confirm that DKK1 inhibits HUVEC tubulogenesis
in vitro (Min et al., 2011) and tumor angiogenesis in an osteosar-
coma xenograft model in vivo.
Employing the RT2 model, we show that TNC promotes
metastasis formation to the lung but not to the liver. This is remi-
niscent of breast cancer where TNC is part of a gene expression
signature specifically associated with lung but not bone metas-
tasis (Minn et al., 2005), an initial observation that has been
subsequently confirmed and functionally validated using xeno-
graft models (Oskarsson et al., 2011; Tavazoie et al., 2008).
Mechanistically, TNC expression was linked to an increased
tumor cell survival and activation of Wnt and Notch signaling,
as revealed by increased expression of Lgr5 and Msi1, respec-
tively (Oskarsson et al., 2011). Although we have shown that
Wnt signaling is activated in TNC-overexpressing RT2 tumors
and in cellular models comprising tumor and endothelial cells
in vitro, the expression of Lgr5 and of several Notch pathway
members are unaffected in the in vivo and in vitro models we
used (Table S3; F.S. andG.O., unpublished data). Multiple expla-
nations for these differences may exist, such as difference in
model systems and in organ and tissue context. We have shown
that the ectopic expression of TNC leads to DKK1 downregula-
tion andWnt signaling activation in RT2/TNC tumors as revealed
by the upregulation of other Wnt target genes, including the
prototypical Wnt target Axin2. Conversely, in RT2/TNCKO tu-
mors DKK1 levels were increased, but Axin2 expression was
unchanged. This result is in line with a previous report showing
that the Wnt pathway has minimal basal activity in pancreatic
beta tumor cells and is dispensable for RT2 tumor progression
(Herzig et al., 2007). In addition to canonical Wnt signaling, the
DKK1 receptor LRP6 was shown to promote PDGF-BB, TGF-b
and CTGF signaling in pericytes and fibroblasts. Importantly,
these signaling activities were blocked by DKK1 through binding
to LRP6 (Ren et al., 2013). We suggest that a TNC-rich matrix
induces a microenvironment with low DKK1 levels that is
susceptible to angiogenic signaling from Wnt and other path-
ways regulated by DKK1. This possibility is supported by our re-
sults that have shown an inverse correlation of TNC and DKK1
expression, promotion of the angiogenic switch by TNC, and a
strong downregulation of DKK1 by TNC in tumor and several
stromal cell types.
In the TNC transgenic RT2 model, we observed that TNC
promotes multiple early events such as proliferation and survival
in hyperplastic islets, Wnt target upregulation in small, differ-
entiated tumors, and the angiogenic switch. A major role of
TNC early in tumorigenesis combined with a less functional
vasculature may explain why macroscopically visible RT2
tumors of the different genotypes did not differ in size. A po-
tential early role of TNC in tumorigenesis has not received
much attention because cancer patient data with a correlation
of high TNC expression and malignancy (Midwood and Orend,
2009; Oskarsson et al., 2011) rather suggested a major role of490 Cell Reports 5, 482–492, October 31, 2013 ª2013 The AuthorsTNC in late events. In human cancer tissue, early events cannot
be easily addressed, which might explain why we did not see a
correlation of TNC and DKK1mRNA expression levels in human
cancer tissues. TNC promotes metastasis (Minn et al., 2005; Os-
karsson et al., 2011; Tavazoie et al., 2008), which has also been
recapitulated here in the RT2 model and in human insulinomas
where the highest TNC expression levels were observed in the
few available metastatic insulinomas.
In summary, we have shown that DKK1 expression is depen-
dent on actin stress fibers that are disrupted by TNC. We have
established a transgenic immune-competent tumor mouse
model that mimics the high expression of TNC observed in
human cancer. Our results prove that TNC plays crucial roles
along tumor progression by promoting early and late events.
We demonstrate that TNC levels determine the extent of tumor
cell survival, invasion, tumor angiogenesis, and metastasis.
These phenotypes appear to be linked to DKK1 downregulation
creating a proangiogenic tumor microenvironment. Finally, our
human TNC-expressing transgenic tumor mice offer a model
for human insulinoma progression and for the preclinical evalua-
tion of drugs that target human TNC.
EXPERIMENTAL PROCEDURES
Mice
Generation of transgenic RipTNC mice, breeding, genotyping, xenograft ex-
periments, and analysis of tumor material are specified in the Supplemental In-
formation. RT2 mice developing pancreatic neuroendocrine tumors (Hanahan,
1985) were crossed with RipTNC (this study) or TNCKO (Forsberg et al., 1996)
mice to generate double-transgenic mice with forced expression of TNC (RT2/
TNC) or lacking TNC expression (RT2/TNCKO). Experiments comprising ani-
mals were performed according to the guidelines of INSERM and the Swiss
Federal Veterinary Office.
Histopathological Analysis of Mouse and Human Tissue
Tumor incidence per mouse was determined as the number of all visible tu-
mors with a minimal diameter of 1 mm. Tumor volume was calculated
assuming a spherical shape with formula V = 1/6 3 p 3 d3 (d = tumor diam-
eter). Pancreata, liver, and lung tissue were isolated, fixed in 4% paraformal-
dehyde (PFA) overnight followed by embedding in paraffin, fixed for 2 hr in
4% PFA, immersed in 20% sucrose overnight, and embedded in Tissue-Tek
O.C.T. (Sakura Finetek) or freshly embedded in O.C.T. and frozen on dry ice.
Histological analysis was performed on 5 mm (paraffin embedded) and 7 mm
(cryopreserved) tissue sections by staining with H&E or immunostaining. Pri-
mary antibodies were incubated overnight at 4C. Immunohistochemical
(IHC) detection was performed on paraffin-embedded tissue using Vectastain
developing system (Vector Laboratories), followed by staining with hema-
toxilin. Detection by IF was performed on fixed or fresh-frozen tissue using
fluorescein-isothiocyanate- or Cy3-coupled secondary antibodies (Jackson
ImmunoResearch Laboratories); cell nuclei were stained with DAPI. Primary
antibodies detecting the following molecules were used: phosphohistone H3
(PH3, 1:200, Upstate 06-570), cleaved caspase-3 (1:50, Cell Signaling Tech-
nology 9661), CD31 (1:50, BD Pharmingen 550274, Acris BM4086), NG2
(1:200, Millipore AB5320), insulin (1:200, Dako Cytomation A0564), glucagon
(1:1000, Sigma G2654), KI67 (1:200, clone SP6, Thermo Scientific, RM-
9106-S1), human TNC (BC-24, 1:3000, Sigma T2551), and fibrinogen (1:500,
Dako A0080). Anti-mouse TNC MTn12 (Aufderheide and Ekblom, 1988) and
anti-human TNCB28.13 antibodies (Schenk et al., 1995) were purified from hy-
bridoma culture supernatants.
Quantification of IF microscopic pictures was done using ImageJ (National
Institutes of Health) software. Staining protocols (fixation, blocking, antibody
dilution) and image acquisition setting (microscope, magnification, light inten-
sity, exposure time) were kept constant per experiment. Data were quantified
as counted events over analyzed tumor area (PH3), as area fraction over
analyzed DAPI-positive cell area (cleaved caspase-3, PH3, and KI67) or as
area fraction over analyzed tumor area (CD31, NG2, and fibrinogen).
Cell-Culture Experiments
Coating of cell-culture dishes with FN and TNC was performed as described
earlier (Huang et al., 2001; Lange et al., 2007). Cells were seeded on the coated
surfaces and analyzed using standard protocols as described. mRNA was ex-
tracted from paraffin-embedded tissue and analyzed by qRT-PCR.
Human Insulinomas
Tumor material was obtained from the Klinikum rechts der Isar (Munich, Ger-
many) or the Hoˆpital de Hautepierre (Strasbourg, France). Analysis of the hu-
man insulinomas had been approved by the respective ethics committees.
All samples were obtained after prior patient informed written consent. Tumor
tissue was obtained from 14 patients (group 1, Munich, and group 2, Stras-
bourg) with endocrine pancreatic cancer and was histopathologically
confirmed as insulinoma by an experienced pathologist. Presence of metas-
tasis was diagnosed in three patients (liver or lymph node n = 2, group 1; liver
and lymph node n = 1, group 2).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.09.014.
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